Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF ‐REVERT trial

ConclusionThe HF-REVERT trial may underpin the concept of miR-132 inhibition to prevent or reverse cardiac remodelling in post-MI HF. The results will inform the design of subsequent outcome trials to test CDR132L in HF.

Source: European Journal of Heart Failure - January 25, 2024 Category: Cardiology Authors: Johann Bauersachs, Scott D. Solomon, Stefan D. Anker, Isabel Antorrena ‐Miranda, Sandor Batkai, Janika Viereck, Steffen Rump, Gerasimos Filippatos, Ulrich Granzer, Piotr Ponikowski, Rudolf A. de Boer, Orly Vardeny, Wilfried Hauke, Thomas Th Tags: Study Design Source Type: research